Dec 19, 2025
Cintas’ Digital Push Is Paying Off With Higher Retention, Analyst Says

Cintas Corporation (NASDAQ:CTAS) stock slipped on Friday despite a modest earnings and revenue beat, as well as a higher full-year outlook. On Thursday, the company reported second-quarter earnings per share of $1.21, beating the analyst consensus estimate of $1.20. Quarterly sales…

Dec 19, 2025
Space Wars, AI Drones, And Wall Street’s New Favorite Trade

Several space and defense technology companies’ stocks moved sharply higher after KeyBanc Capital Markets initiated coverage across the group, as investors reacted to bullish long-term growth commentary and newly established price forecasts tied to defense modernization and the expanding commercial…

Dec 19, 2025
FedEx Domestic Package Services Are Driving Growth, Bullish Analyst Says

FedEx Corporation (NYSE:FDX) on Thursday reported second-quarter revenue of $23.5 billion, beating analyst estimates of $22.79 billion and adjusted earnings of $4.82 per share, beating estimates of $4.11 per share. FedEx now expects revenue to be up 5% to 6% in fiscal 2026, versus prior guidance for growth…

Dec 19, 2025
BlackBerry Lifts Outlook, But Analysts Warn Of QNX Deceleration

BlackBerry Limited (NYSE:BB) stock fell on Friday despite a third-quarter earnings and revenue beat, as well as a higher fiscal 2026 outlook. Investors instead focused on analyst caution around slowing QNX growth, overshadowing stronger profitability and resilient Secure Communications performance.…

Dec 19, 2025
Accenture’s AI Momentum Impresses Analysts Despite Early-Stage Rollouts

Accenture Plc (NYSE:ACN) executives on the first-quarter earnings call said client demand has increased steadily over the past nine quarters, with roughly 100 incremental clients initiating AI projects during that period. Management cautioned, however, that AI deployments remain in early…

Dec 19, 2025
FDA Puts Cassava’s Simufilam Epilepsy Trial On Full Clinical Hold

Cassava Sciences Inc. (NASDAQ:SAVA) received a formal letter from the U.S. Food and Drug Administration (FDA) related to the company’s trial for simufilam Following previously reported communications with the FDA regarding Cassava’s investigational new drug application and proposed proof-of-concept clinical…